Gerrit Los

Dr. Gerrit Los is a highly accomplished scientist and leading expert in multiple disciplines including oncology, translational medicine, and pharmacology. He has led numerous successful scientific and commercial collaborations and has supported and contributed to the clinical development of multiple oncology compounds, delivering lead candidates to patients. Gerrit served as Director of Cancer Biology and Senior Director of the Oncology Research Unit at Pfizer between 2002 – 2012. In these roles, his achievements included directing teams in the development of ground-breaking targeted cancer therapeutics such as the novel first-in-class kinase inhibitors crizotinib and palbociclib and other highly successful treatments such as axitinib. Most recently, he served as Vice President of Pharmacology at AnaptysBio, San Diego, where he directed the preclinical development of 2 lead compounds in preparation for Phase 1 clinical trials and contributed to AnaptysBio’s immuno-oncology program.

Gerrit provided leadership and strategic direction for Five Prime Therapeutics in South San Francisco from 2012 – 2015 and drove the development of several oncology assets including innovative proteins and immuno-oncology therapies. Prior to Pfizer, he was an Adjunct Professor at the University of California San Diego where he built and directed one of their pharmacogenomics/molecular pharmacology programs which focused on developing and understanding the role of prognostic markers in tumour responses. Before leading this innovative research work in San Diego, Gerrit directed a research team in preclinical drug development and optimization of local drug delivery at the Netherlands Cancer Institute in Amsterdam. He received his PhD in Oncology/Pharmacology from the Free University in Amsterdam, the Netherlands and was a Dutch Cancer Society post-doctoral fellow at the Netherlands Cancer Institute. To date, he has published more than 100 peer-reviewed papers, is a contributor of 8 book chapters and has more than 250 published abstracts. He is also a reviewer for multiple high impact cancer journals.